Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Oncol.

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1674965

The Effect of Traditional Chinese Medicine on Patients Undergoing Targeted Therapy for Liver Cancer: A Systematic Review and Meta-Analysis

Provisionally accepted
Hongting  YanHongting Yan1Yingjie  LiYingjie Li2Bin  GuoBin Guo3*Bing  YangBing Yang1*Dongxin  TangDongxin Tang1*
  • 1Guizhou University of Traditional Chinese Medicine, Guiyang, China
  • 2Integrated Hospital of Traditional Chinese Medicine of Southern Medical University, Guangzhou, China
  • 3Other

The final, formatted version of the article will be published soon.

Objective: Evaluate the therapeutic efficacy and safety of Traditional Chinese Medicine(TCM)in patients with primary liver cancer (PLC) receiving targeted therapy. Methods: We conducted a comprehensive search of databases. The search scope covered the period from the establishment of the databases to April 2025. We included 49 randomized controlled trials (RCTs) evaluating targeted therapy for primary liver cancer with TCM. Efficacy and safety outcomes were assessed using risk ratios (RR), standardized mean differences (SMD), and their 95% confidence intervals (CI). Results: Targeted therapy for liver cancer patients who received TCM treatment showed improvements in objective response rate (ORR) (RR, 1.49 [1.33-1.66], P < 0.0001), disease control rate (DCR) (RR, 1.32 [1.25,1.40], P < 0.0001), the 1-year survival (RR, 1.50 [1.20,1.88]; P = 0.0004) and Karnofsky Performance Status (KPS) (SMD, 1.34 [0.86,1.81]; P < 0.0001), and can reduce the incidence of adverse events, as well as to some extent decrease the production of tumor markers and related inflammatory factors. Conclusion: TCM enhances the efficacy and safety of targeted therapy in PLC, offering superior clinical outcomes with fewer adverse effects. These findings support its potential integration into standard treatment protocols.

Keywords: primary liver cancer, targeted therapy, Traditional Chinese Medicine, Systematic review, Meta-analysis

Received: 28 Jul 2025; Accepted: 09 Oct 2025.

Copyright: © 2025 Yan, Li, Guo, Yang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Bin Guo, guobin1902@163.com
Bing Yang, 1006019442@qq.com
Dongxin Tang, tangdongxin@sina.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.